These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 7194066)

  • 1. [Human i.v. immune globulin by chemical modification with beta-propiolactone/radiochemical study (author's transl)].
    Stephan W; Fasold H
    Arzneimittelforschung; 1980; 30(12):2090-3. PubMed ID: 7194066
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Beta-propiolactone as a sterilizing agent in the manufacture of intravenous immunoglobulin preparations].
    Stephan W; Dichtelmüller H
    Arzneimittelforschung; 1983; 33(9):1230-1. PubMed ID: 6416260
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Placental transfer of class G immunoglobulins treated with beta-propiolactone (beta-PL) for intravenous application--a case report.
    Höckel M; Kaufmann R
    J Perinat Med; 1986; 14(3):205-8. PubMed ID: 3783391
    [TBL] [Abstract][Full Text] [Related]  

  • 4. On the mutagenicity and immunogenicity of a beta-propiolactone-treated therapeutic IgG-preparation.
    Pincus JH; Mortelmans K; Tanaka W; Stephan W; Lissner R
    Arzneimittelforschung; 1981; 31(11):1924-8. PubMed ID: 6172136
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Gaseous sterilizers (author's transl)].
    Ducel G
    Schweiz Rundsch Med Prax; 1975 Dec; 64(52):1670-4. PubMed ID: 1219711
    [No Abstract]   [Full Text] [Related]  

  • 6. Effect of beta-propiolactone on routine biochemical investigations.
    Dooley BJ; Harling NP; Lloyd G; van Heyningen C
    Med Lab Sci; 1985 Oct; 42(4):318-21. PubMed ID: 4079681
    [No Abstract]   [Full Text] [Related]  

  • 7. [Chemical modification with beta-propiolactone as a general concept for the production of intravenously tolerable immunoglobulin preparations].
    Stephan W
    Beitr Infusionther Klin Ernahr; 1983; 11():20-5. PubMed ID: 6686024
    [No Abstract]   [Full Text] [Related]  

  • 8. [The reaction of beta-propiolactone with serum proteins and amino acid derivatives (author's transl)].
    Determann H; Joachim HU
    Z Klin Chem Klin Biochem; 1971 Sep; 9(5):398-401. PubMed ID: 5173516
    [No Abstract]   [Full Text] [Related]  

  • 9. Effect of beta-propiolactone treatment on the complement activation mediated by equine antisera.
    Guidolin R; Morais JF; Stephano MA; Marcelino JR; Yamaguchi IK; Higashi HG
    Rev Inst Med Trop Sao Paulo; 1997; 39(2):119-22. PubMed ID: 9394526
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of beta-propiolactone on some routine haematological tests.
    Atrah HI; Allardyce M; Davidson RJ
    Med Lab Sci; 1988 Oct; 45(4):308-11. PubMed ID: 3268715
    [No Abstract]   [Full Text] [Related]  

  • 11. [Principles of selective inactivation of the viral genome. III. Kinetics of the inactivation of bacteriophage MS2 infectivity by beta-propiolactone].
    Budovskiĭ EI; Zalesskaia MA
    Mol Biol (Mosk); 1985; 19(4):1139-47. PubMed ID: 4047036
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Beta-propiolactone for cold sterilization of heart valve transplants].
    Wutzler P; Sprössig M; Wenzel KP; Mücke H
    Z Exp Chir; 1975; 8(4):236-40. PubMed ID: 1053182
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Elimination of complement fixation of gamma-globulin by chemical modification with beta-propiolactone].
    Stephan W
    Z Klin Chem Klin Biochem; 1969 May; 7(3):282-6. PubMed ID: 4187787
    [No Abstract]   [Full Text] [Related]  

  • 14. Quantitative assays for evaluation of HTLV-III inactivation procedures: tri(N-butyl)phosphate:sodium cholate and beta-propiolactone.
    Prince AM; Horowitz B; Dichtelmueller H; Stephan W; Gallo RC
    Cancer Res; 1985 Sep; 45(9 Suppl):4592s-4594s. PubMed ID: 2410108
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term tolerance and recovery of beta-propiolactone/ultraviolet (beta PL/UV) treated PPSB in chimpanzees.
    Stephan W; Kotitschke R; Prince AM; Brotman B
    Thromb Haemost; 1981 Aug; 46(2):511-4. PubMed ID: 7302890
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Cultivation of mycoplasma in fluid media sterilized with beta-propiolactone].
    Kiuntsel' V; Starost E; Meissner Kh
    Vestn Akad Med Nauk SSSR; 1976; (5):60-2. PubMed ID: 969882
    [No Abstract]   [Full Text] [Related]  

  • 17. [Longterm therapy with i.v.-gamma-globulin in children (author's transl)].
    Kornhuber B
    Monatsschr Kinderheilkd (1902); 1979 Jan; 127(1):20-2. PubMed ID: 83534
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Elimination and organ distribution of intravenously administered allogeneic and xenogeneic IgG modifications. (Standard IgG, F (ab)2-fragments and beta-propiolactone treated IgG) in dogs.
    Ring J; Duswald KH; Bachmann T; von Scheel J; Stephan W; Brendel W
    Res Exp Med (Berl); 1978 Sep; 173(3):209-18. PubMed ID: 364571
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inactivation of retroviruses by beta-propiolactone.
    Lancet; 1985 Jan; 1(8419):56. PubMed ID: 2856986
    [No Abstract]   [Full Text] [Related]  

  • 20. [Potency studies of sample rabies vaccine, inactivated by beta-propiolactone].
    Akan E
    Turk Hij Tecr Biyol Derg (1961); 1976; 36(2):172-88. PubMed ID: 1023462
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.